ADVA
20.2.2020 07:02:54 CET | Business Wire | Press release
ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for Q4 and full year 2019 ended on December 31, 2019. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200219006045/en/
Q4 2019 financial summary 1
(in thousands of EUR) |
Q4 |
Q4 |
Change |
Q3 |
Change |
|
|||
|
2019 |
2018 |
|
2019 |
|
|
|||
|
|
||||||||
Revenues |
151,135 |
131,513 |
14.9% |
144,310 |
4.7% |
|
|||
Pro forma gross profit |
54,633 |
48,665 |
12.3% |
49,086 |
11.3% |
|
|||
in % of revenues |
36.1% |
37.0% |
-0.9pp |
34.0% |
2.1pp |
|
|||
Pro forma operating income |
10,333 |
8,106 |
27.5% |
7,393 |
39.8% |
|
|||
in % of revenues |
6.8% |
6.2% |
0.6pp |
5.1% |
1.7pp |
|
|||
Operating income 2 |
5,438 |
6,332 |
-14.1% |
3,200 |
69.9% |
|
|||
Net income 2 |
2,522 |
3,633 |
-30.6% |
2,190 |
15.2% |
|
|||
|
|
|
|
|
|||||
(in thousands of EUR) |
Dec. 31 2019 |
Dec. 31 2018 |
Change |
Sep. 30 2019 |
Change |
|
|||
Cash and cash equivalents |
54,263 |
62,652 |
-13.4% |
38,396 |
41.3% |
|
|||
Net debt 3 |
61,146 |
26,832 |
127.9% |
74,873 |
-18.3% |
|
|||
1
Potential differences due to rounding
2
Q4 including EUR 3.2 million and Q3 including EUR 2.5 million one-off expenses
3
Q4 2019 including EUR 34.4 million and Q3 2019 including EUR 36.2 million lease liabilities due to first-time adoption of IFRS 16
Q4 2019 IFRS financial results
Revenues for Q4 2019 increased by 4.7% to EUR 151.1 million from EUR 144.3 million in Q3 2019 and grew significantly by 14.9% from EUR 131.5 million in the same year-ago period. Revenues for Q4 2019 were at the upper end of the guidance corridor the company provided on October 24, 2019, of between EUR 142 million and EUR 152 million.
Pro forma operating income for Q4 2019 was EUR 10.3 million (6.8% of revenues), up from EUR 7.4 million (5.1% of revenues) in Q3 2019 and above EUR 8.1 million (6.2% of revenues) in the same year-ago period. Pro forma operating income for Q4 2019 was also at the upper end of the company’s guidance range of between 5% and 7% of revenues.
Operating income for Q4 2019 of EUR 5.4 million increased from EUR 3.2 million reported for Q3 2019 but decreased compared to EUR 6.3 million in the same year-ago quarter. This is mainly due to tariffs on China-made products in the US market, the strength of the US dollar and one-off expenses of EUR 3.2 million in Q4 2019. These one-off expenses are primarily driven by selective head count reduction and site closures.
Net income for Q4 2019 was EUR 2.5 million and increased by 15.2% from EUR 2.2 million in Q3 2019; however, it declined from EUR 3.6 million in Q4 2018.
At quarter-end, the company’s cash and cash equivalents totaled EUR 54.3 million, representing a substantial increase of 41.3% compared to EUR 38.4 million at the end of Q3 2019.
The company’s net debt decreased by EUR 13.8 million to EUR 61.1 million from EUR 74.9 million at the end of Q3 2019.
Net working capital at quarter-end was EUR 128.2 million compared to EUR 137.8 million at the end of Q3 2019. Although revenues increased in Q4, ADVA managed to decrease net working capital by EUR 9.6 million, mainly due to reduction of trade account receivables.
2019 annual summary 1
(in thousands of EUR) |
2019 |
2018 |
Change |
|
|
Revenues |
556,821 |
501,981 |
10.9% |
|
|
Pro forma gross profit |
195,364 |
185,621 |
5.2% |
|
|
in % of revenues |
35.1% |
37.0% |
-1.9pp |
|
|
Pro forma operating income |
24,811 |
23,266 |
6.6% |
|
|
in % of revenues |
4.5% |
4.6% |
-0.1pp |
|
|
Operating income 2 |
12,003 |
14,989 |
-19.9% |
|
|
Net income |
7,045 |
9,678 |
-27.2% |
|
|
|
|
||||
(in thousands of EUR) |
Dec. 31 2019 |
Dec. 31 2018 |
Change |
|
|
Cash and cash equivalents |
54,263 |
62,652 |
-13.4% |
|
|
Net debt 3 |
61,146 |
26,832 |
127.9% |
|
|
1
Potential differences due to rounding
2
2019 including EUR 5.7 million one-off expenses
3
2019 including EUR 34.4 million lease liabilities due to first-time adoption of IFRS 16
For the full year 2019, revenues increased by 10.9% to EUR 556.8 million from EUR 502.0 million in 2018. The positive development is due to solid demand from all customer groups across all technology areas. Except for Q1 2019, quarterly revenues increased sequentially in 2019.
Pro forma gross profit increased by 5.2% from EUR 185.6 million in 2018 to EUR 195.4 million in 2019. Pro forma gross margin, however, decreased from 37.0% in 2018 to 35.1% in 2019. The margin was impacted by the US tariffs on Chinese-made goods in the US market and the strong US dollar.
Pro forma operating income for 2019 was EUR 24.8 million (4.5% of revenues), compared to EUR 23.3 million (4.6% of revenues) in 2018. Operating income for 2019 was EUR 12.0 million compared to EUR 15.0 million in 2018 and decreased by EUR 3.0 million. Operating income 2019 includes one-off expenses of EUR 5.7 million. These one-off expenses are primarily driven by selective head count reduction and site closures.
In 2019, ADVA generated a net income of EUR 7.0 million, down by EUR 2.7 million after EUR 9.7 million in the prior year.
Basic and diluted earnings per share in 2019 amounted to positive EUR 0.14, both compared to basic and diluted earnings per share of EUR 0.19 in 2018.
Management commentary
“Today, we report one of the best results in our 25-year company history,” commented Uli Dopfer, CFO, ADVA. “Both of our two key metrics were at the upper end of our guidance range, and year-over-year we increased revenues significantly by 14.9%. On an annualized basis our revenue grew by more than 10% – an excellent result that even exceeded our self-imposed goals and was supported by satisfactory profitability. We are finalizing our restructuring and preparing for the uncertainty caused by COVID-19. It is currently difficult for us to assess what impact the crisis in China will have on our 2020 results. The city of Wuhan is an important center for photonic components and subsystems, and the isolation of the region will lead to delays in the global supply chain. We expect that despite the healthy order backlog, some of the order fulfillment and revenue recognition will shift from Q1 2020 to later quarters. However, in light of the positive order entry and strong demand, we are very confident of further increasing annual revenues and profitability compared to 2019.”
“Numerous factors that caused market uncertainty and tension in the past year will continue to be relevant in 2020. However, we adjusted very well to the new boundary conditions and once again showed that the DNA of our company guarantees stable and reliable results even in difficult times,” said Brian Protiva, CEO, ADVA. “Despite the trade tensions, we held our course and developed our business with great discipline. Throughout the year we were able to sequentially increase our revenues and gain market share in certain segments. ADVA is in an excellent position for the coming years. We have created a solid basis in all three technology areas and see interesting growth scenarios as a result of transformational change disrupting our markets.”
2020 financial outlook
For the full year 2020, ADVA expects revenues to exceed EUR 580 million and a pro forma operating income of greater than 5% of revenues.
The company will publish its financial results for Q1 2020 on April 23, 2020.
Conference call details
ADVA will hold a conference call for analysts and investors today, February 20, 2020, to discuss these results and management’s outlook. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CET (9:00 a.m. EDT). A question and answer session will follow management presentations.
To participate, please dial the appropriate number at least five minutes before the start time and ask for the ADVA conference call.
International number: +49 69 201 744 210
US number: +1 877 423 0830
Pin code: 743 752 65#
A corresponding presentation is available on ADVA’s website:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls
The complete annual report 2019 (January – December) is available as a PDF here:
https://www.adva.com/en/about-us/investors/financial-results/financial-statements
A replay of the call will be available here:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls
Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.
Use of pro forma financial information
ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219006045/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
